## Clinical Assessment This patient presents with moderate LUTS (IPSS 22) secondary to BPH with: - Objective findings: smooth, symmetrically enlarged prostate on DRE - Elevated PVR (80 mL, normal <30 mL) - Normal PSA (2.8 ng/mL, no malignancy concern) - No prior pharmacotherapy ## Management Algorithm for BPH ```mermaid flowchart TD A[BPH with LUTS]:::outcome --> B{Symptoms bothersome?}:::decision B -->|No| C[Watchful waiting + lifestyle modification]:::action B -->|Yes| D{Prostate size + PVR?}:::decision D -->|Small-moderate, PVR <100 mL| E[Alpha-blocker monotherapy]:::action D -->|Large prostate, elevated PVR| F[Alpha-blocker ± 5-ARI]:::action D -->|Severe symptoms, large gland, high PVR| G[Consider TURP/minimally invasive]:::action E --> H[Reassess at 4-6 weeks]:::action F --> H ``` ## Why Alpha-Blocker First? **Key Point:** Alpha-blockers (tamsulosin, alfuzosin, doxazosin) are first-line pharmacotherapy for symptomatic BPH because they: 1. Provide rapid symptom relief (within 1–2 weeks) 2. Work via smooth muscle relaxation in the prostate and bladder neck 3. Have no dependence on prostate size 4. Are well-tolerated with predictable side effects **High-Yield:** IPSS 22 = moderate symptoms warranting pharmacotherapy. PVR 80 mL is elevated but not severe enough to mandate surgery immediately. ## Role of 5-Alpha Reductase Inhibitors | Feature | Alpha-Blocker | 5-ARI | |---------|---|---| | Onset | 1–2 weeks | 3–6 months | | Mechanism | Smooth muscle relaxation | Prostate volume reduction | | Best for | Rapid symptom relief | Large prostate (>40 g), PSA >1.5 ng/mL | | Combination | Not indicated initially | Added if inadequate response to alpha-blocker alone | **Clinical Pearl:** 5-ARIs (finasteride, dutasteride) take months to work and are reserved for: - Large prostate glands (>40 g on ultrasound) - Elevated PSA with BPH - Inadequate response to alpha-blocker monotherapy - Prevention of acute urinary retention and need for surgery This patient does not yet meet criteria for 5-ARI monotherapy. ## Why Not TURP Immediately? **Warning:** TURP is reserved for: - Refractory LUTS despite maximal medical therapy (≥6 months) - Recurrent acute urinary retention - Recurrent UTIs due to residual urine - Large bladder stones secondary to BPH - Renal insufficiency from outlet obstruction This patient is treatment-naïve and has not failed conservative management. ## Why Not Urodynamic Studies? **Key Point:** Urodynamic studies are NOT routine in uncomplicated BPH. They are indicated only when: - Diagnosis is uncertain (e.g., concurrent detrusor dysfunction) - Considering invasive surgery in atypical presentations - Neurogenic lower urinary tract dysfunction is suspected This patient has a classic BPH presentation; urodynamics would delay necessary treatment.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.